Literature DB >> 3606928

ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

I D Bradbrook, H N Magnani, H C Moelker, P J Morrison, J Robinson, H J Rogers, R G Spector, T Van Dinther, H Wijnand.   

Abstract

ORG 10172 is a heparinoid with mean molecular weight 6500 daltons. Intravenous bolus injections of ORG 10172 were compared with placebo and heparin injections in 91 separate studies in 83 healthy male subjects. 6400 units ORG 10172 produced a mean maximum change of 14.7 s in kaolin cephalin time (c.f. greater than 120 s for 5000 units heparin). Changes in prothrombin time were minimal (1.6 s for 6400 units ORG 10172 and 4.5 s after 5000 units heparin). A dose-related increase in bleeding time occurred after ORG 10172 and at high doses (greater than 3200 units) some secondary bleeding, which was never serious, occurred at between 1 and 4 h after incision. A dose-dependent reduction in ex vivo platelet adhesiveness was found at 10 min after ORG 10172 injection. ORG 10172 promoted a much smaller release of lipoprotein lipase as compared with heparin. The effect of ORG 10172 on plasma factor Xa activity (one measure of its action) was described by a biexponential decay with a mean distribution half-life of 2.34 (s.e. mean 0.16) h and mean disposition half-life of 17.6 (s.e. mean 1.1) h. It thus has a much longer duration of effect than heparin. There was a linear relationship of plasma anti-Xa response to increasing dose although there was some variability only partly explained by differences in body weight or surface area. ORG 10172 administration by bolus intravenous injection was well tolerated and there was no evidence of adverse effects on clinical chemistry or haematology tests.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606928      PMCID: PMC1386160          DOI: 10.1111/j.1365-2125.1987.tb03100.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

Review 1.  Heparins--anionic polyelectrolyte drugs.

Authors:  L B Jaques
Journal:  Pharmacol Rev       Date:  1979-06       Impact factor: 25.468

2.  Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion.

Authors:  V P Young; A R Giles; J Pater; W E Corbett
Journal:  Thromb Res       Date:  1980 Dec 1-15       Impact factor: 3.944

3.  Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin.

Authors:  C J Carter; J G Kelton; J Hirsh; M Gent
Journal:  Thromb Res       Date:  1981 Jan 1-15       Impact factor: 3.944

4.  Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin.

Authors:  E Holmer; U Lindahl; G Bäckström; L Thunberg; H Sandberg; G Söderström; L O Anderson
Journal:  Thromb Res       Date:  1980-06-15       Impact factor: 3.944

5.  Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.

Authors:  F A Ofosu; G Modi; A L Cerskus; J Hirsh; M A Blajchman
Journal:  Thromb Res       Date:  1982-11-15       Impact factor: 3.944

6.  Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction.

Authors:  P A Ockelford; C J Carter; L Mitchell; J Hirsh
Journal:  Thromb Res       Date:  1982-11-01       Impact factor: 3.944

7.  Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.

Authors:  D P Mikhailidis; M A Barradas; A M Mikhailidis; H Magnani; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

8.  Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications.

Authors:  C P Henny; H Ten Cate; J W Ten Cate; S Surachno; H van Bronswijk; J M Wilmink; P A Ockelford
Journal:  Lancet       Date:  1983-04-23       Impact factor: 79.321

9.  A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.

Authors:  D G Meuleman; P M Hobbelen; G van Dedem; H C Moelker
Journal:  Thromb Res       Date:  1982-08-01       Impact factor: 3.944

10.  Heparin therapy in venous thromboembolism.

Authors:  J E Wilson; L J Bynum; R W Parkey
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

View more
  13 in total

1.  Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.

Authors:  András Gruber; Ulla M Marzec; Leslie Bush; Enrico Di Cera; José A Fernández; Michelle A Berny; Erik I Tucker; Owen J T McCarty; John H Griffin; Stephen R Hanson
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

Review 2.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure.

Authors:  Shun-Ichi Kimura; Jun Odawara; Takatoshi Aoki; Masayuki Yamakura; Masami Takeuchi; Yoshihiko Watanabe; Kosei Matsue
Journal:  Int J Hematol       Date:  2009-04-21       Impact factor: 2.490

4.  Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.

Authors:  J C Stiekema; H P Wijnand; T G Van Dinther; H C Moelker; J Dawes; A Vinchenzo; H Toeberich
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

Review 5.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 6.  Danaparoid: a review of its use in thromboembolic and coagulation disorders.

Authors:  Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits.

Authors:  M Sasaki; C M Herd; C P Page
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

8.  A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.

Authors:  J C Stiekema; J M Van Griensven; T G Van Dinther; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

Review 9.  The design and synthesis of new synthetic low-molecular-weight heparins.

Authors:  K Chandarajoti; J Liu; R Pawlinski
Journal:  J Thromb Haemost       Date:  2016-04-15       Impact factor: 5.824

10.  Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.

Authors:  A de Boer; J C Stiekema; M Danhof; T G van Dinther; J K Boeijinga; A F Cohen; D D Breimer
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.